- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- States Rush To Figure Out How To Enforce Trump’s Medicaid Work Requirements
- Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
- Maine law increases oversight of healthcare transactions: 6 notes for dental leaders
- Align Technology sees 6.2% increase in Q1 revenue: 7 notes
- 8 behavioral healthcare M&A deals in 2026
- Maryland autism therapy provider expands in-home services in Colorado
- 5 ways insurers are betting big on AI
- AHA warns of Chinese cyber actors using covert networks
- Will AI anxiety drive a new wave of talent to health systems?
- ‘There are no easy solutions’: What dental leaders told us in April
- 4 ways to improve hospital at home
- Connecticut House passes bill authorizing at-home dental hygiene visits
- Virtua Health eliminates 15K excess hospital days with Microsoft AI
- Delaware physician to pay $180K to settle fraud allegations
- UHS deployed 8 AI solutions in revenue cycle in 2025, eyes clinical operations
- Houston Methodist ranked most innovative health system in US — here’s how its leaders define that
- Tennessee specialist group joins Maury Regional Medical Group
- ‘Take the robot out of the human’: Health systems redeploy staff in the AI era
- New Jersey ASC performs robotic spine surgery milestone
- Aviation, hospitality and the NFL: What dentistry can learn from other industries
- HCA California system names COO
- Virginia expands noncompete limits for terminated employees
- Over half of dental professionals dealing with burnout: Report
- Parkview Health breaks ground on freestanding ED, urgent care facility
- Jefferson Health lands $1.7M grant for hypertension care
- 22 behavioral health executive moves to know
- The ‘significant opportunity’ Talkspace will bring to UHS
- Physician lawsuit rates hit historic lows, but malpractice premiums are soaring: AMA
- The potential ‘litigation wave’ headed for GI
- ASCs’ multi-billion dollar savings potential
- Dental’s new cash-pay anesthesia opportunity
- The new cash-pay anesthesia opportunity
- Healthcare costs remain a top concern for voters as midterms loom: KFF
- UHS-owned behavioral health facility to lay off 648 employees
- PeaceHealth physician group switch-up heads to court
- Teladoc Health reports strong momentum behind BetterHelp insurance shift, CEO says
- Georgia Southern University to begin construction of new dental school
- AI Tool May Help Identify ADHD in Kids Long Before Typical Diagnosis
- Tennessee dental school to open clinic in Kentucky
- Federal autism committee outlines policy, care gaps in HHS letter
- Tennessee provider expands virtual behavioral health urgent care
- Chicago invests $16.2M in mental health, street psychiatry program
- US suicide rate declines 2%: 5 things to know
- FDA Moves to Real-Time Clinical Trial Patient Monitoring, Faster Drug Review
- AstraZeneca CEO's conservative MFN model excludes reference markets from forecast
- With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis
- Universal Health Services' Q1 2026 earnings growth dampened by volume hits
- AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde
- Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years
- Only 1 in 4 employers able to ‘absorb’ increasing health benefit costs without impacting business
- Dementia Screening Safe For Families, Trial Finds
- Online Program Soothes Post-Trauma Stress In Injured Children
- Mental Defeat Can Worsen Chronic Pain, Researchers Say
- Pooled Umbilical Cord Blood Boosts Stem Cell Transplant Success, Trial Finds
- New GSK CEO’s first quarter boosted by Shingrix surge as Exdensur stumbles in switch trial
- AstraZeneca restarts £300M investment in UK, but Merck not budging
- Chiesi lays out $1.9B to bolster rare disease offerings with KalVista buyout
- US drugmaker’s reputations shift quickly amid political pressures, job cuts: survey
- Saving Lives by Changing Lives: The Next Frontier in Suicide Prevention
- Trump’s Medicaid Work Mandate Debuting in Nebraska to Much Dismay
- Pfizer looks to jump start Elrexfio with topline win in second-line myeloma
- The push to expand access to emergency contraception
- Humana pulls back the curtain on planning for 2027 MA bids
- Lawmakers introduce bill to expand mental health clinics
- What 5 dentists would do differently in their careers
- On Capitol Hill, health system CEOs agree to 'rational reworking' of site-neutral payments
- Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies
- Secret to Surviving 'Perfect Mom' Posts on Social Media Revealed
- Pfizer’s victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Getting All Your Ducks in a Row to IPO: Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Remarks to the Small Business Capital Formation Advisory Committee
- FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting
- CDC Warns of Antibiotic-Resistant Salmonella in Backyard Flocks
- Listen to the Latest ‘KFF Health News Minute’
- AI-driven coding platform Arintra rolls out new documentation improvement capabilities
- Florida Delays Children's Health Insurance Expansion as Uninsured Rate Rises
- Interoperability was Never the Finish Line in Healthcare
- Interoperability was Never the Finish Line in Healthcare
- IKS Health to acquire TruBridge in $557M deal
- FDA turns up heat on Amgen, proposing to rescind approval of Tavneos
- Rocket sells priority review voucher for $180M after Kresladi gene therapy approval
- Big companies position themselves for payday from $50B federal rural health fund
- AZ's Breztri nabs FDA asthma nod, adding fuel to blockbuster launch
- Haleon scores branding goal with star-studded soccer offensive
- Daylight Saving Time Fails to Boost Daily Steps, Study Finds
- Metabolic Syndrome Tied To Cancer Risk
- Mail-In Colon Cancer Test Kits Offer Affordable Screening
- U.S. Dentists Still Overprescribing Opioids Compared To Other Nations, Puerto Rico
- Novartis stands by $5B Pluvicto goal despite European regulatory setback, bispecific competition
- Big Companies Position Themselves for Payday From $50B Federal Rural Health Fund
- An Urgent Care Treated Her Allergic Reaction. An ER Monitored Her — For $6,700.
- Centene swings to $1.5B profit as Medicaid business improves even as ACA membership falls by 2 million
- CCS deploys enterprise-wide agentic AI across chronic care operations
- Utah Medical Licensing Board urges state to shut down Doctronic AI prescribing pilot
- Estrogen Patch Shortages Likely Driven By Empowered Women Seeking Relief, Expert Says
- GSK's Tesaro unit dealt pre-trial blow in Jemperli feud with AnaptysBio
- Medical professional liability premiums rise for 7th straight year
- UChicago Medicine, Artisight partner on system-wide rollout of smart hospital platform
- Solace Health expands care navigation services to commercially insured patients
- First Gene Therapy for Genetic Hearing Loss, Otarmeni, Gains FDA Approval
- Mundipharma, CorMedix eye antifungal expansion after Rezzayo trial win
- CMS Extends Medicare's Short-Term Bridge Program for GLP-1 Obesity Drug Coverage
- Humana's CenterWell, Mark Cuban Cost Plus Drugs partner to tackle employers' drug costs
- Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts
- Astellas counts on new medicines to offset projected Xtandi decline in fiscal 2026
- Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
- AMA urges lawmakers to implement stronger safeguards for AI chatbots in mental health
- Blood Glucose Monitors Improve Control Among Type 2 Diabetes Patients
- Regaining Weight After Quitting Your GLP-1 Drug? A Simple Procedure Might Help, Study Says
- Late-Night Noshing Could Contribute To Stress-Related Bathroom Problems
- New Treatment Targets Unaddressed Major Symptom Of Depression Through Joy, Pleasure and Purpose
- Florida Delays Children’s Health Insurance Expansion as Uninsured Rate Rises
- The Help That Many Older Americans Need Most
- UnityAI builds out agentic AI for staffing operations to match outpatient clinicians with patient demand
- Why Pricier Olive Oil May Be Better For Your Brain
- Your Internal Signal to Stop Eating is More Complex Than Previously Thought
- Gounder Culls the News, From Ticks and AI to Who Might Lead CDC
- FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
- Green Lighting Capital Formation: Remarks at the SEC International Institute on Capital Formation
- HCA Healthcare executives shrug off Q1 volumes disruptions, reaffirm FY2026 guidance
- With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
- New Plan Could Speed Medicare Coverage for Innovative Devices
- Former Tobacco Executive Takes CDC Role
- Heated Socks Sold at Costco Recalled After Burn Reports
- First Measles Case of the Year Reported in New Jersey
- CMS, FDA Announce RAPID Coverage Pathway to Accelerate Device Reimbursement
- CMS, FDA Announce RAPID Coverage Pathway to Accelerate Device Reimbursement
- Health Tech Weekly Rundown: Google invests in AI training for rural health workers; State of genAI adoption in healthcare
- Does Motherhood Shield You From Stroke?
- These Fun Pursuits Help Middle-Aged Folks Protect Brain Health, Study Finds
- New Guidelines Highlight Behavioral Therapy For Insomnia
- Playing Pretend Provides Unexpected Benefits For Growing Kids
- New Survey Estimates 8 Million Americans Used Psilocybin in 2024
- Eye Photos Might Offer Early Warning Of Chronic Health Problems, AI Study Finds
- A look at payers' attitudes toward specialty drug management
- 988 Hotline Leads to Fewer Suicides Among Young People, Study Finds
- Drop in NIH Funding Delays Thousands of Studies
- U.K. Plans To Ban Cigarette Sales for Future Generations
- Website Helps Dementia Patients And Caregivers Bond, Reminisce
- Gene Cure For Inherited Deafness Effective, Long Lasting, Clinical Trial Finds
- New Treatment, Dato-DXd, Improves Survival for Aggressive Breast Cancer
- ER Study Finds Major Gaps in Measles Immunity
- Opening Remarks at the 32nd Annual International Institute for Securities Market Growth and Development
- Keynote Remarks at The Economic Club of Washington
- Rethinking Prior Authorization for Better Outcomes
- Statement on the Amendments to Form PF
- Update on the SEC’s Work Toward Treasury Clearing Implementation
- A look at the National Academy of Medicine’s Change Maker Accelerators Program
Not exactly over-the-counter, actually pharmacist prescribed birth control pills:
Over-the-counter birth control hitting shelves, thanks to Michigan firm
- The FDA decided last year that a longtime birth control pill was safe enough to gain over-the-counter status.
- The drug, Opill, is the product of a Grand Rapids-based company which has headquarters in Ireland, too.
- The pill began shipping Monday at a cost of $20 a month, or $50 for a three-month supply.
By Robin Erb - March 4, 2024
The first over-the-counter daily birth control pill began shipping to pharmacies Monday, dramatically boosting convenience and access among oral contraceptives, especially for low-income women, those living in rural areas and those without easy access to transportation or child care.
On Monday, Opill — which is offered in a 28-day blister pack and is 98% effective against unplanned pregnancies when taken as directed — became available for the first time nationally.
It is the product of drugmaker Perrigo, which is based both in Grand Rapids and Ireland.The drug is being manufactured in Ireland, and its active ingredient, norgestrel, is being manufactured in Germany.
After months of anticipation by medical groups and consumer groups, the company announced the first, long-awaited shipments Monday morning.
“It’s revolutionary in terms of having women take control of their reproductive choices,” said Dr. Ann Gillett-Elrington, a staff physician and board-certified obstetrician at Western Wayne Family Health Centers.
The suggested retail price will be $20 for a one-month supply, $50 for a three-month supply and $90 for a six-month supply.
The relatively low cost is good news, especially for the uninsured or without regular medical care, she said.
“Appointments — sometimes they're far in between. People can get pregnant in the interval,” she said. “They also have to take time off from work (for an appointment) and they might have to make child arrangements.”
Given the cost of those things or an unplanned pregnancy, the pill “is very cost-effective,” she said.
The pill will be available at major retail pharmacies, including Walgreens and CVS, and through Amazon, said Perrigo’s chief commercial officer, Sara Young, who called the pill “groundbreaking.”
The French drugmaker HRA Pharma had begun seeking FDA approval for its over-the-counter product when Perrigo purchased the company in a sale completed in 2022.
Opill will also be sold online directly to consumers from opill.com on March 18, she said.
Long awaited
The U.S. Food and Drug Administration switched Opill, a progestin-only tablet, to an over-the-counter drug in July. Because it doesn’t contain the hormone estrogen, it may have few side effects. Most common side effects are irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps or bloating, according to the FDA’s July announcement.
The drug had originally been approved in 1973. In making its decision last year, the FDA made it clear that the pill was safe and effective enough that Americans could decide on their own — with consulting with a doctor — whether Opill is appropriate for them.
That’s “obviously a very important step forward regarding convenience and access,” said Dr. Mark Fendrick, an internal medicine doctor and director of the Center for Value-Based Insurance Design at the University of Michigan.
About 26 million Americans are uninsured, according to the U.S. Census, making it difficult or too expensive to get regular medical care, he said.
Family planning, including options for oral contraception, is “a very effective, equitable and important public health and population health measure,” he said, so Opill is a “great step forward for access.”
Moreover, limitations or bans on abortion in some states make pregnancy prevention even more critical.
For its part, Right to Life of Michigan, aligning with national leaders of Right to Life, takes no position on products that prevent an egg’s fertilization, legislative director Genevieve Marnon, told Bridge Michigan, Monday.
Still unknown is whether insurers, including the state’s Medicaid program, will cover the costs of the pill.
The pill likely will show up at local pharmacies later this month, said Farah Jalloul, state emergency preparedness coordinator at the Michigan Pharmacists Association. And pharmacies can decide whether they will carry the pill, she noted, though she added that most undoubtedly will do so.
When it hits the shelves, it will be available to consumers of any age — a concern for some who worry about adolescents or some adults who might be unable to follow directions or understand contraindications.
Among those who should not take Opill are women with a history of breast cancer. People who have any other form of cancer should consult their doctor before taking Opill. And Opill is not for use as emergency contraception nor does it prevent sexually transmitted infections.
Ideally, said Gillett-Elrington at Western Wayne Family Health Centers, a young person or an adult with questions will talk with a trusted medical professional before taking Opill, though there are no guarantees, she acknowledged.
The drug works mainly by thickening a person’s cervical mucus, thereby blocking sperm from reaching the egg. Opill also may prevent an egg from implanting or altogether block its release from the ovaries. But a pill from the 28-day blister pack must be taken every day.
More than one in three women using oral contraceptives (36%) had missed taking doses because they were unable to get their next supply, according to a 2022 KFF Women’s Health Survey.Medical groups, including the American Medical Association, had urged the FDA to approve over-the-counter daily contraception. And the American College of Obstetricians and Gynecologists Monday lauded the release, and released guidelines for clinicians.
ACOG President Dr. Verda J. Hicks, called Opill a safe drug for patients of all ages, including adolescents.
It’s a “key component of reproductive health care” in a country where there are “increasing healthcare deserts … where people do not have access to gynecologic care,” she said in a prepared statement.
Despite some initial concerns that consumers might not be able to understand how to take the pills or why some patients should not take the pills, ACOG doctors “trust our patients to determine if this OTC method is best for them.”
Perrigo executed a corporate tax inversion to Ireland eleven years ago to avoid U.S. corporate taxes. It was 'acquired' by Irish-based Elan Corporation for $ 8.6 billion. The combined company is now known as Perrigo Company plc.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















